*b@Fmb#F

sK )fm Ad8A(eI(2 b u,uAa,ZA }n9~*~^*93 KV 1kBmU 1^`~ *v1QQ 2!RkLwRkw Lz; *#m#hc#mvc %DOQwzjQpm A_8 vj0vo/. W0gE0s0 uc f$v? KC5?9oB @! -MUjyU {0q}iqkGi0q u:%zOx:Hu !s|2c @2 8bYn \^\J n RTnFbFjhqu :wI {oRcx&7 F/@*^~ de WgmWI4 x4FeXnFF.

qN$XN`Nq
PxYIWYI kmlR X@ Nvev8-w(
aikIP
`@sQsAWQU@3
VTT[XTT
`@sQsAWQU@3
\0
`@sQsAWQU@3
6_6 Nq
`@sQsAWQU@3
)6) BVK
`@sQsAWQU@3
7K M(m
`@sQsAWQU@3
LGL |x^
`@sQsAWQU@3
$z$ O$jP$ k7/7 #6O0H
`@sQsAWQU@3
Q:|O4yl%bf *7gE*gZ @F8Oee bt]+^hth8+{Q
`@sQsAWQU@3
+X TLLᵃ
`@sQsAWQU@3
878 0a
`@sQsAWQU@3
I%I V11
`@sQsAWQU@3
LGL |x^
`@sQsAWQU@3
$3$ ww M,,] !d!!f!bg
`@sQsAWQU@3
#zxoz!u
`@sQsAWQU@3
%451^^ l/{jO{/{~jXX
`@sQsAWQU@3
%451^^ l/{jO{/{~jXX
`@sQsAWQU@3
1!1 Ef, FAz |N| X//
`@sQsAWQU@3
%m(sqq V5|=yn5n7=wk
`@sQsAWQU@3
&s& )$#
`@sQsAWQU@3
]!] IoeRo
`@sQsAWQU@3
MEe/%Eh |`|mN;dio] =QI5-6IZO5K
`@sQsAWQU@3
xmRmL {}SB)___b
`@sQsAWQU@3
vJJ^0,G,ZL y/q&_ _{hx-}}-c_}{
`@sQsAWQU@3
SihOG`,O~ /h/ gjM~== 12E2\2P\2WE onO@e@O@tKL
`@sQsAWQU@3
PQ 7P@Hw xdxox
`@sQsAWQU@3
-w U~ :z+}+
`@sQsAWQU@3
{U~{ #dZ6Z
`@sQsAWQU@3
w{T};fG s,1t1
`@sQsAWQU@3
A, &GUGKcK
`@sQsAWQU@3
TM J411
`@sQsAWQU@3
Gb G[qq
`@sQsAWQU@3
mf ZyPP
`@sQsAWQU@3
x* m1|mN:1
`@sQsAWQU@3
Zi ZG(
`@sQsAWQU@3
JC ~nn
`@sQsAWQU@3
B# :sE
`@sQsAWQU@3
ixkD RVV
`@sQsAWQU@3
nh \rUtU iYC2sC)h926CY [5sdH$Fe!5oU
`@sQsAWQU@3
}z &6}%1 ql^q mPW(W
`@sQsAWQU@3
rn^t^ Xs#n ~C^e0E/o10C^
`@sQsAWQU@3
J6 x0r n+M-/ mn:\c$
`@sQsAWQU@3
J6 x0r n+M-/ mn:\c$
`@sQsAWQU@3
J6 x0r n+M-/ mn:\c$
`@sQsAWQU@3
zYj[z yEc,3f
`@sQsAWQU@3
Meev/b/
`@sQsAWQU@3
TM J411
`@sQsAWQU@3
|; CZnMnᵇ
`@sQsAWQU@3
)|YbWh, :%HbHᵇ
`@sQsAWQU@3
,Mh \^TLTᵇ
`@sQsAWQU@3
A- (mH!!ᵇ
`@sQsAWQU@3
9r 7J{lo Cuq
`@sQsAWQU@3
U7 eAc-q V0/
`@sQsAWQU@3
~Q~_e9v_X ^c
`@sQsAWQU@3
zYj[z yEc,3f
`@sQsAWQU@3
zYj[z yEc,3f
`@sQsAWQU@3
zYj[z yEc,3f
`@sQsAWQU@3
zYj[z yEc,3f
`@sQsAWQU@3
zYj[z yEc,3f
`@sQsAWQU@3
uM xuu rwdS:4 ~EOd
`@sQsAWQU@3
4? u[c[
`@sQsAWQU@3
X!A2UAUz!z
`@sQsAWQU@3
dn:nPdP
`@sQsAWQU@3
LrS )XnX Rd,d0dA0dX, joKpNpKpEiZ
`@sQsAWQU@3
=8Ws8
`@sQsAWQU@3
zYj[z yEc,3f
`@sQsAWQU@3
b;,K t/M |B
`@sQsAWQU@3
zYj[z yEc,3f

7! Yu 2vSvt+ nbn0

mAmgen collaboration; BeiGene has China commercial rights. tEnsem collaboration; BeiGene has global rights. ;DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. iLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. xZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. `Amgen collaboration; BeiGene has development and commercialization rights in China. wIn combination with Zanubrutinib. pMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login